Clinical trials: Sepsis Syndromes
Escherichia Coli Bacteremia, Klebsiella Bacteraemia
Switch to Oral Antibiotics in Gram-negative Bacteremia
Eligible subjects will be those age 18 years or more with mono-microbial blood stream infection caused by E. coli, Klebsiella species, Enterobacter species, Serratia species, Citrobacter species, or Proteus species, who have…
- Conditions
- Escherichia Coli Bacteremia, Klebsiella Bacteraemia, Enterobacter Bacteraemia, Serratia Bacteraemia
- Trial name
- SOAB (NCT04146922)
- Testing
- Step down to oral antimicrobial therapy, IV antimicrobial therapy
- Where
- 7 sites in Bahrain, Kuwait and 2 more
- Volunteers
- 176 people
- Sponsor
- Hamad Medical Corporation
Sepsis, Intoxication; Septic
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Sepsis.
This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of sepsis.
- Trial name
- NCT03764085
- Testing
- Rheosorbilact®, Ringer lactate
- Where
- 13 sites in Georgia, Kazakhstan and 3 more
- Volunteers
- 180 people
- Sponsor
- Yuria-Pharm
Bacteremia, Gram-Positive Bacterial Infections
Linezolid in the Treatment of Hemodialysis Patients With Catheter-Related Gram-Positive Bloodstream Infections
This study will treat hemodialysis patients who have a central catheter that is thought to be infected with a specific bacteria (Gram positive bacteria).
- Trial name
- NCT00108433
- Testing
- Cefazolin IV, Linezolid IV, Vancomycin (IV)
- Where
- 17 sites in United States, Colombia and 5 more
- Volunteers
- 61 people
- Sponsor
- Pfizer
Sepsis, Hypotension
Fluid Responsiveness Evaluation in Sepsis-associated Hypotension
This study assesses the mean difference in fluid balance at ICU discharge and associated patient outcomes, based on a dynamic assessment of fluid responsiveness in septic patients with refractory hypotension in an ICU setting.
- Trial name
- FRESH (NCT02837731)
- Testing
- Treatment Starling SV monitor
- Where
- 12 sites in United States, United Kingdom
- Volunteers
- 150 people
- Sponsor
- Cheetah Medical Inc.
Acute Kidney Injury
Efficacy Study of a Selective Cytopheretic Device (SCD) in Patients With Acute Kidney Injury
The purpose of this protocol is to evaluate the safety of a selective cytopheretic device (SCD) in patients that are on continuous renal replacement therapy (CRRT) for acute kidney injury (AKI).
- Trial name
- NCT01400893
- Testing
- SCD
- Where
- 26 sites in United States
- Volunteers
- 134 people
- Sponsor
- SeaStar Medical
Sepsis, Septic Shock
Combined Hemoperfusion and Therapeutic Plasma Exchange for Treatment of Patients With Septic Shock
Sepsis is a critical burden for a healthcare. From 2000 to 2020, the number of publications and clinical studies on the topic of Sepsis and septic shock on the National Library of Medicine resource The National Center for…
- Trial name
- NCT06404424
- Testing
- Efferon LPS, Efferon CT
- Where
- Russia
- Volunteers
- 82 people
- Sponsor
- Efferon JSC
Cytokine Storm (Covid-19)
Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm
This was a randomized, double-blind, placebo-controlled, 29-day, multicenter study to assess the efficacy and safety of ruxolitinib + standard-of-care (SoC) therapy, compared with placebo + SoC therapy, in patients aged ≥12 years…
- Trial name
- RUXCOVID (NCT04362137)
- Testing
- Ruxolitinib
- Where
- 61 sites in United States, Argentina and 10 more
- Volunteers
- 432 people
- Sponsor
- Novartis Pharmaceuticals
Sepsis, Severe Sepsis
Plasma Inducible Nitric Oxide Synthase (iNOS) Assay and Sepsis Study
The primary objective is to demonstrate that the plasma inducible nitric oxide synthase (iNOS) assay (PliNOSa® test) has an acceptable relative risk ratio for predicting the onset of sepsis within 72 hours of testing when…
- Conditions
- Sepsis, Severe Sepsis, Septic Shock
- Trial name
- PliNOSa® Test (NCT01371929)
- Volunteers
- 166 people
- Sponsor
- Research & Diagnostic Antibodies
Candidemia, Mycoses
Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation
The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.
- Conditions
- Candidemia, Mycoses, Fungal Infection, Fungemia
- Trial name
- ReSPECT (NCT04368559)
- Testing
- Rezafungin for Injection, Posaconazole, Fluconazole
- Where
- 53 sites in United States, Belgium and 7 more
- Volunteers
- 602 people
- Sponsor
- Mundipharma Research Limited
Candidemia, Candidiasis
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
To evaluate the efficacy and safety of intravenous micafungin for the treatment of patients with proven or probable fungal infections caused by Candida sp.
- Trial name
- NCT01982071
- Testing
- Micafungin
- Where
- 15 sites in China
- Volunteers
- 59 people
- Sponsor
- Astellas Pharma China, Inc.
Invasive Candidiasis, Candidemia
Micafungin Versus Fluconazole in the Treatment of Invasive Candidiasis and Candidemia
To determine the efficacy and safety of micafungin (FK463) versus fluconazole (Diflucan) in treating patients with invasive candidiasis or candidaemia
- Trial name
- NCT00189709
- Testing
- Micafungin, fluconazole
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Astellas Pharma Inc
COVID-19
A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients
The primary purpose of Stage-I of this study is to evaluate the safety and tolerability of OP-101 in patients with severe COVID-19 and of Stage 2 of this study is to evaluate the efficacy of OP-101 in patients with severe…
- Trial name
- PRANA (NCT04458298)
- Testing
- OP-101
- Where
- 8 sites in United States
- Volunteers
- 28 people
- Sponsor
- Ashvattha Therapeutics, Inc.
Pneumonia, Sepsis
A Safety and Efficacy Study of Hospitalized Patients With Community-Acquired Pneumonia and Sepsis
The objective of this study is to demonstrate the safety and efficacy of IC14 in the treatment of hospitalized patients with community-acquired pneumonia and sepsis.
- Trial name
- NCT00042588
- Testing
- Recombinant Chimeric Monoclonal Antibody
- Where
- United States
- Sponsor
- ICOS Corporation
Augmented Renal Clearance (ARC), Systemic Inflammatory Response Syndrome (SIRS)
Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance
To evaluate the pharmacokinetic (PK) profiles of ceftaroline and avibactam in adults with augmented renal clearance (ARC).
- Trial name
- NCT01624246
- Testing
- Ceftaroline fosamil/Avibactam (CXL)
- Where
- 21 sites in United States, Australia
- Volunteers
- 12 people
- Sponsor
- Forest Laboratories
Acute Pancreatitis With Uninfected Necrosis, Unspecified
Hemoperfusion Efferon СT for the Treatment of Patients With Acute Pancreatitis
Mortality from severe acute pancreatitis reaches 42%. The prognosis of acute pancreatitis is associated with the development of acute inflammatory response syndrome (SIRS) and multiple organ failure (MOF).
- Trial name
- NCT05695001
- Testing
- Efferon CT
- Where
- Russia
- Volunteers
- 34 people
- Sponsor
- Efferon JSC
Staphylococcus Aureus, Bacteremia
Efficacy, Immunogenicity, and Safety of a Single Dose of V710 in Adult Patients Scheduled for Cardiothoracic Surgery (V710-003 AM2)
This study will assess the efficacy of a single dose of V710 vaccine to prevent serious Staphylococcus aureus infections following elective cardiothoracic surgery.
- Conditions
- Staphylococcus Aureus, Bacteremia, Mediastinitis
- Trial name
- NCT00518687
- Testing
- V710
- Volunteers
- 8,031 people
- Sponsor
- Merck Sharp & Dohme LLC
Sepsis, Sepsis Associated DIC
A Study to Learn About the Occurrence of Disseminated Intravascular Coagulation in People With Sepsis and Further Worsening of Sepsis
This is an exploratory study in which data from people with sepsis (a serious condition in which the body responds to an infection that damages vital organs) admitted to an Intensive care unit (ICU) who will receive treatment are…
- Trial name
- NCT06986798
- Testing
- Local standard medical care
- Where
- 31 sites in Austria, Belgium and 5 more
- Volunteers
- 150 people
- Sponsor
- Bayer
Nosocomial Infections, Sepsis
Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants
The purpose of this study is to show whether Veronate, a donor-selected staphylococcal human immune globulin intravenous (IGIV), can prevent an infection in the blood caused by staphylococcal bacteria in premature babies weighing…
- Conditions
- Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
- Trial name
- NCT00113191
- Testing
- Veronate
- Where
- 93 sites in United States, Canada
- Volunteers
- 2,000 people
- Sponsor
- Bristol-Myers Squibb
Neonatal Sepsis
Late-onset Sepsis in Term and Pre-term Neonates and Infants up to 3 Months of Age
This study evaluated the safety, pharmacokinetics and efficacy of ceftobiprole in term and pre-term newborn babies and infants up to 3 months of age with late-onset sepsis (LOS).
- Trial name
- NCT05856227
- Testing
- Ceftobiprole medocaril
- Where
- 14 sites in United States, Bulgaria and 6 more
- Volunteers
- 9 people
- Sponsor
- Basilea Pharmaceutica
COVID-19, Infectious Disease
Continuous Temperature Telemonitoring of Patients With COVID-19 and Other Infectious Diseases in Hospital at Home Using Viture
The aim of this cohort study is to validate Viture®, a continuous temperature telemonitoring system, evaluating the level of agreement with a standard commercially available digital axillary thermometer.
- Conditions
- COVID-19, Infectious Disease, Tract Infection, Urinary, Bacteremia
- Trial name
- Viture (NCT05959928)
- Testing
- Continuous wearable thermometer placed on patient's armpit to monitor body temperature remotely
- Where
- Spain
- Volunteers
- 208 people
- Sponsor
- Vitio Medical S.L.